Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan T Swords

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Blood Cancer Discovery|September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
Nature|October 19, 2018
Functional genomic landscape of acute myeloid leukaemiaJeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, et al.
Cancer Cell|July 22, 2022
Integrative analysis of drug response and clinical outcome in acute myeloid leukemiaDaniel Bottomly, Nicola Long, Anna Reister Schultz, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Blood Cancer Discovery|September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Haematologica|November 6, 2025
<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapyFieke W Hoff, Ying Huang, Rina Li Welkie, et al.
Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.
Blood Advances|August 7, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapyFieke W Hoff, William G Blum, Ying Huang, et al.
American Journal of Hematology|July 3, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMAFieke W Hoff, Joshua F Zeidner, Geeta Torlapati, et al.
Nature|October 19, 2018
Functional genomic landscape of acute myeloid leukaemiaJeffrey W Tyner, Cristina E Tognon, Daniel Bottomly, et al.
Cancer Cell|July 22, 2022
Integrative analysis of drug response and clinical outcome in acute myeloid leukemiaDaniel Bottomly, Nicola Long, Anna Reister Schultz, et al.
Pageof 3